This story has been updated to provide more earnings details and company background.
Cell Therapeutics Inc. generated $1.1 million in revenue through European sales of its cancer drug Pixuvri, but still posted a $19.4 million loss for the first quarter of 2013.
That’s more than the $17.4 million loss for the first quarter of 2012.
As of March 31, Cell Therapeutics’ cash and cash equivalents totaled $44.3 million. That’s up from 2012, when the company had $27.4 million in cash and cash equivalents…
This story has been updated to provide more earnings details and company background.
Cell Therapeutics Inc. generated $1.1 million in revenue through European sales of its cancer drug Pixuvri, but still posted a $19.4 million loss for the first quarter of 2013.
That’s more than the $17.4 million loss for the first quarter of 2012.
As of March 31, Cell Therapeutics’ cash and cash equivalents totaled $44.3 million. That’s up from 2012, when the company had $27.4 million in cash and cash equivalents…